Canton Strategic Holdings (CNTN) Short-Term Debt issuances (2022 - 2025)
Canton Strategic Holdings posted quarterly Short-Term Debt issuances of -$23746.0 for Q2 2025, down 107.69% on a QoQ basis from $308924.0 in Q1 2025.
Canton Strategic Holdings (CNTN) has 4 years of Short-Term Debt issuances data on file, last reported at -$23746.0 in Q2 2025.
- For the quarter ending Q2 2025, Short-Term Debt issuances changed N/A year-over-year to -$23746.0; the trailing twelve-month figure through Dec 2025 stood at $285178.0 (down 27.61% YoY), and the FY2025 full-year result was $285178.0, down 27.61% from the prior year.
- Short-Term Debt issuances for Q2 2025 stood at -$23746.0, down from $308924.0 in the prior quarter.
- Across five years, Short-Term Debt issuances topped out at $917472.0 in Q1 2022 and bottomed at -$23746.0 in Q2 2025.
- The 4-year median for Short-Term Debt issuances is $393960.0 (2024), against an average of $462677.0.
- The widest annual swing landed in 2024, when Short-Term Debt issuances slumped 45.04%; it then decreased 21.58% in 2025.
- A 4-year view of Short-Term Debt issuances shows it stood at $917472.0 in 2022, then dropped by 21.88% to $716775.0 in 2023, then plunged by 45.04% to $393960.0 in 2024, then plunged by 106.03% to -$23746.0 in 2025.
- The last three Short-Term Debt issuances figures came in at -$23746.0 (Q2 2025), $308924.0 (Q1 2025), and $393960.0 (Q1 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -33,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Canton Strategic Holdings | 643.89 Mn | 602.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -23,746.00 |
| Jun 30, 2025 | -23,746.00 |
| Mar 31, 2025 | 308,924.00 |
| Mar 31, 2025 | 308,924.00 |
| Mar 31, 2024 | 393,960.00 |
| Mar 31, 2024 | 393,960.00 |
| Mar 31, 2023 | 716,775.00 |
| Mar 31, 2023 | 716,775.00 |
| Mar 31, 2022 | 917,472.00 |
| Mar 31, 2022 | 917,472.00 |